Document is current

Article History

Received: 28 April 2025

Accepted: 16 June 2025

First Online: 2 July 2025

Declarations

:

: Bruce Strober: Consultant (honoraria): AbbVie, Alumis, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Janssen, LEO, Eli Lilly, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB, RAPT, Regeneron, Sanofi-Genzyme, UNION Therapeutics; Stock Options: Connect Biopharma, Mindera Health; Speaker: AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme; Scientific Co-Director (consulting fee): CorEvitas Psoriasis Registry; Investigator: CorEvitas Psoriasis Registry; Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. Manish Patel, Mark I. Kaldas, Greg St. John, and Huzefa Photowala are employees of AbbVie, Inc, and may hold AbbVie stock or stock options. Adam P. Sima, Thomas Eckmann, and Alicia Beeghly are employees of CorEvitas, LLC (formerly Corrona, LLC), and stockholders of Thermo Fisher Scientific, Inc. CorEvitas is supported through contracted subscriptions with multiple pharmaceutical companies. The manuscript was a collaborative effort between CorEvitas and AbbVie, with financial support provided by AbbVie. April Armstrong has served as a research investigator and/or scientific adviser to AbbVie, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, EPI, Incyte, LEO, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed.

: The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central institutional review board (IRB, Advarra, Protocol number is Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs (see Table  in the Electronic Supplementary Material for details), and documentation of approval was submitted to the sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participating.